Work

Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx367.039

Authors: J. Wang, J. Nemunaitis, G. Chiorean, P. Lorusso, K. Courtney, A. Olguin, J. Bullington, S. Shemesh, J. Chen, C. Brooks, T.M. Bauer

Institutions: Mary Crowley Cancer Research Center, University of Washington, Yale Cancer Center, Yale University, The University of Texas Southwestern Medical Center, Stemline Therapeutics (United States), Tennessee Oncology

Language: English

Topic: Nuclear Structure and Function

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2762034783

FWCI:

Cites:

Cited by:

Related to: 10